37–80%
Reported response rates
Across selected Phase 1b studies in metastatic gynecologic cancers and non-Hodgkin lymphoma.
02 / Evidence
Selected signals supporting continued development.
These headline figures are drawn from the supplied source materials and should be reconciled with final study, regulatory, and intellectual-property records before external release.
Up to 100×
Drug-loading comparison
Described in the draft materials relative to traditional ADC architecture.
3
FDA-cleared INDs
Cited in the current executive source material for investigator-initiated studies.
32
Issued patents
Reported alongside five peer-reviewed publications and three abstracts or posters.